Editas Medicine. has been granted a patent for enzymatically active Cas9 (eaCas9) fusion molecules. These molecules consist of an eaCas9 linked to a template nucleic acid, enabling gene editing applications. The patent includes various forms of Cas9 and types of nucleic acids for enhanced gene editing systems. GlobalData’s report on Editas Medicine gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Editas Medicine, CRISPR genome editing was a key innovation area identified from patents. Editas Medicine's grant share as of July 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Enzymatically active cas9 fusion molecules for gene editing
The granted patent US12049651B2 introduces a novel Cas9 fusion molecule designed for gene editing applications. This molecule consists of an enzymatically active Cas9 protein covalently linked to a template nucleic acid via a polypeptide linker. The Cas9 can be selected from various forms, including wild-type, nickase, split, or inducible Cas9. The template nucleic acid can be either single-stranded or double-stranded. The claims further specify that the Cas9 molecule may contain surface-exposed cysteine residues, thiol groups, or specific modifications to the template nucleic acid, such as maleimide or acrydite modifications. The polypeptide linker can vary in length and may include specific amino acid sequences.
Additionally, the patent outlines a comprehensive gene editing system that incorporates the Cas9 fusion molecule along with guide RNA (gRNA) molecules. This system is designed to target specific nucleic acids, facilitating the generation of double-strand breaks that can be repaired through various DNA repair pathways, ultimately leading to modified target nucleic acids. The claims also describe methods for modifying target nucleic acids in cells using the Cas9 fusion molecule and gRNA, emphasizing the potential for precise genetic alterations. The patent highlights the versatility of the Cas9 fusion molecule and its applications in gene editing, including the use of multiple Cas9 nickase molecules to create specific cleavage events in target nucleic acids.
To know more about GlobalData’s detailed insights on Editas Medicine, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
